A Study of TG103 Injection in Type 2 Diabetes Subjects
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.
Also called NCT05348122
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Registry
-
NCT05348122
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05348122. Randomized; single masking; primary purpose treatment. Start 2022-06-15 (anticipated); primary completion 2023-11-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of TG103 Injection in Type 2 Diabetes Subjects
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- TG103,Q2W
- Intervention (Drug)
- TG103,QW
- Intervention (Drug)
- Placebo,Q2W
- Intervention (Drug)
- Placebo,QW
- Intervention (Drug)
- Dulaglutide,QW
- Lead sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct05348122- Content hash
c68431633972f330d25e44f08e0950c2882844c959d345b250b9cade81cac85f